Compare AbbVie Inc (ABBV) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs FuelCell Energy Inc — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while FuelCell Energy Inc trades at $22.97 (market cap $1.76B). The key difference: AbbVie Inc is far larger — about 255.6× FuelCell Energy Inc's market cap, and AbbVie Inc pays a 2.72% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| ABBV | FCEL | |
|---|---|---|
Market Cap | $449.91B | $1.76B |
Sector | Health | Industrials |
52-Week High | $261.07 | $36.01 |
52-Week Low | $184.85 | $3.92 |
Enterprise Value | $513.38B | $1.60B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
FCEL trades at $25.96, down 7.65% amid a $200 million stock offering announcement, yet maintains a bullish technical signal with support near $25. Revenue grew to $158.16M in 2025, but profitability remains challenged with a net income margin of -132.41%. Recent news highlights a 5 GW proposal pipeline, with 90% tied to data center power demand, and a $49 million EXIM financing boost for global expansion.
The outlook is speculative; growth potential from AI-driven data center deals and clean energy exports is offset by persistent losses, negative cash flow from operations, and dilution risk from equity offerings. Analyst consensus is mixed with a $20.13 price target, suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
